Table 4. Open in new tab Summary of the...

IMID

Studies

With IBD/Without IBD

Main Findings (Comparison of Patients With and Without Co-occurring IBD)

Multiple sclerosis

66/251

□ Lower occurrence of advanced multiple sclerosis in terms of a primary progressive (5% vs 15%; P = .05) or secondary progressive (19% vs 35%; P = .05)

□ Lower median EDSS and a lower proportion of patients had EDSS >4

□ Less frequent relapse of, and disease progression of, multiple sclerosis.

□ Less need for multiple sclerosis–related therapies, including immunomodulators

AIP

4/64

□ A numerically higher recurrence rate of AIP; a similar rate of extrapancreatic involvement

AIH

17/17

□ A lower remission rate, a higher treatment failure rate, and more frequent progression to cirrhosis

Asthma

12/15

□ An FEV₁ and a lower ratio of FEV₁ to FVC

Eosinophilic esophagitis

2239/102 048

□ Lower risk of food embolus and lower risk of needing endoscopic esophageal stricture dilatation

Hidradenitis suppurativa

20/182

□ No difference in severity in terms of Hurley stage

Table 4.

Open in new tab

Summary of the impact of IBD on other IMIDs

IMID	Studies	With IBD/Without IBD	Main Findings (Comparison of Patients With and Without Co-occurring IBD)
Multiple sclerosis	2	66/251	□ Lower occurrence of advanced multiple sclerosis in terms of a primary progressive (5% vs 15%; P = .05) or secondary progressive (19% vs 35%; P = .05)
			□ Lower median EDSS and a lower proportion of patients had EDSS >4
			□ Less frequent relapse of, and disease progression of, multiple sclerosis.
			□ Less need for multiple sclerosis–related therapies, including immunomodulators
AIP	1	4/64	□ A numerically higher recurrence rate of AIP; a similar rate of extrapancreatic involvement
AIH	1	17/17	□ A lower remission rate, a higher treatment failure rate, and more frequent progression to cirrhosis
Asthma	1	12/15	□ An FEV₁ and a lower ratio of FEV₁ to FVC
Eosinophilic esophagitis	1	2239/102 048	□ Lower risk of food embolus and lower risk of needing endoscopic esophageal stricture dilatation
Hidradenitis suppurativa	1	20/182	□ No difference in severity in terms of Hurley stage

IMID	Studies	With IBD/Without IBD	Main Findings (Comparison of Patients With and Without Co-occurring IBD)
Multiple sclerosis	2	66/251	□ Lower occurrence of advanced multiple sclerosis in terms of a primary progressive (5% vs 15%; P = .05) or secondary progressive (19% vs 35%; P = .05)
			□ Lower median EDSS and a lower proportion of patients had EDSS >4
			□ Less frequent relapse of, and disease progression of, multiple sclerosis.
			□ Less need for multiple sclerosis–related therapies, including immunomodulators
AIP	1	4/64	□ A numerically higher recurrence rate of AIP; a similar rate of extrapancreatic involvement
AIH	1	17/17	□ A lower remission rate, a higher treatment failure rate, and more frequent progression to cirrhosis
Asthma	1	12/15	□ An FEV₁ and a lower ratio of FEV₁ to FVC
Eosinophilic esophagitis	1	2239/102 048	□ Lower risk of food embolus and lower risk of needing endoscopic esophageal stricture dilatation
Hidradenitis suppurativa	1	20/182	□ No difference in severity in terms of Hurley stage

Abbreviations: AIH, autoimmune hepatitis; AIP, autoimmune pancreatitis; EDSS, Expanded Disability Status Scale; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; IBD, inflammatory bowel disease; IMID, immune-mediated inflammatory disease.

This Feature Is Available To Subscribers Only